Skip to main content

View Resource

Published

Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.
Ogbuagu O. The Lancet Infectious Diseases 2025;:https://doi.org/10.1016/S1473-3099(25)00238-5.
[We aimed to assess the efficacy, safety, and tolerability of obeldesivir for the treatment of COVID-19 in non-hospitalised individuals at low risk of progression to severe disease. Obeldesivir was generally safe and well tolerated, with greater reduction of SARS-CoV-2 viral RNA copy number versus placebo at day 5. However, obeldesivir did not significantly reduce time to symptom alleviation.]
Available with an NHS OpenAthens password
Age Groups
Adults
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Community Clinics
General Practice
Staff Groups
Drug Therapy